Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

被引:28
|
作者
Otten, Julia [1 ]
Ryberg, Mats [1 ]
Mellberg, Caroline [1 ]
Andersson, Tomas [1 ]
Chorell, Elin [1 ]
Lindahl, Bernt [1 ]
Larsson, Christel [2 ]
Holst, Jens Juul [3 ,4 ]
Olsson, Tommy [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
[2] Univ Gothenburg, Dept Food & Nutr & Sport Sci, Gothenburg, Sweden
[3] Univ Copenhagen, NNF Ctr Basal Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
基金
瑞典研究理事会;
关键词
GASTRIC-INHIBITORY POLYPEPTIDE; PEPTIDE-1; RELEASE; INCRETIN HORMONE; ORAL GLUCOSE; RISK-FACTORS; INSULIN; FAT; MAINTENANCE; SECRETION; METABOLISM;
D O I
10.1530/EJE-19-0082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state.
引用
收藏
页码:417 / 427
页数:11
相关论文
共 50 条
  • [21] Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
    Le Roux, C.
    Steen, O.
    Lucas, K. J.
    Ekinci, E., I
    Startseva, E.
    Unseld, A.
    Hennige, A. M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [22] CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
    Cazzo, Everton
    Gestic, Martinho Antonio
    Utrini, Murillo Pimentel
    Pareja, Jose Carlos
    Chaim, Elinton Adami
    Geloneze, Bruno
    Lazzarinibarreto, Maria Rita
    Magro, Daniela Oliveira
    ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, 2016, 29 (04): : 257 - 259
  • [23] GLP-1 and GIP levels and effect are markedly enhanced one month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes
    Laferrere, Blandine
    Tran, Hao C.
    Yap, Kimberly P.
    Heshka, Stanley
    McGinty, James
    Teixeira, Julio
    Olivan, Blanca
    DIABETES, 2007, 56 : A374 - A375
  • [24] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    Roux, Carel W. le
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hennige, Anita M.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 162 - 173
  • [25] Intra-pancreatic fat is associated with high circulating glucagon and GLP-1 concentrations following whey protein ingestion in overweight women with impaired fasting glucose: A randomised controlled trial
    Lim, Jia Jiet
    Sequeira-Bisson, Ivana R.
    Yip, Wilson C. Y.
    Lu, Louise W.
    Miles-Chan, Jennifer L.
    Poppitt, Sally D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 207
  • [26] Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
    Frias, Juan Pablo
    Nauck, Michael A.
    Van, Joanna
    Kutner, Mark E.
    Cui, Xuewei
    Benson, Charles
    Urva, Shweta
    Gimeno, Ruth E.
    Milicevic, Zvonko
    Robins, Deborah
    Haupt, Axel
    LANCET, 2018, 392 (10160): : 2180 - 2193
  • [27] Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis
    Aronne, L.
    Harris, M. S.
    Roberts, M. S.
    Suschak, J.
    Tomah, S.
    He, L.
    Yang, J.
    Frias, J. P.
    Browne, S. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S33 - S34
  • [28] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
    Choi, Jae Duk
    Baek, Seungjae
    Kim, Youngmin
    Eun, Kahee
    Kwon, Se Chang
    Morrow, Linda
    Hompesch, Marcus
    Kang, Jahoon
    DIABETES, 2019, 68
  • [29] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    Urva, Shweta
    Coskun, Tamer
    Loh, Mei Teng
    Du, Yu
    Thomas, Melissa K.
    Gurbuz, Sirel
    Haupt, Axel
    Benson, Charles T.
    Hernandez-Illas, Martha
    D'Alessio, David A.
    Milicevic, Zvonko
    LANCET, 2022, 400 (10366): : 1869 - 1881
  • [30] Effects of milk protein concentrate supplementation on metabolic parameters, adipocytokines and body composition in obese women under weight-loss diet: study protocol for a randomised controlled trial
    Haidari, Fatemeh
    Elahikhah, Mahsa
    Islam, Sheikh Mohammed Shariful
    Mohammadshahi, Majid
    Shahbazian, Hajieh
    Aghamohammadi, Vahideh
    BMJ OPEN, 2022, 12 (10):